AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

Johnson & Johnson is a stock that's full of risk these days. Its single-digit growth numbers don't look all that exciting, either.

Forget Johnson & Johnson: Buy This Better Healthcare Stock Instead

Altimmune

Amgen

Structure Therapeutics Inc

Merck

Viking Therapeutics

Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ).

7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025

AstraZeneca has begun the worldwide withdrawal of its COVID vaccine - ending an era in which it saved millions of lives while being dogged by controversy.

AstraZeneca starts worldwide withdrawal of COVID vaccine

LONDON — The pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled, according to the EU medicines regulator.

AstraZeneca pulls its COVID-19 vaccine from the European market

Pharmaceutical giant AstraZeneca on Wednesday said it planned to withdraw its Covid-19 vaccine as demand for it has declined.

AstraZeneca to withdraw Covid vaccine worldwide, citing a drop in demand

AstraZeneca said it's withdrawing its COVID-19 vaccine worldwide, with the company saying there's a surplus of available vaccines that are available.

AstraZeneca withdraws COVID-19 vaccine

AstraZeneca has witnessed a significant increase in its market valuation, adding more than £3 billion as it announced the global withdrawal of its COVID-19 vaccine. The company's shares rose by 1.6 percent, contributing to a new record high for the FTSE 100.

AstraZeneca gets £3 billion valuation boost following global vaccine withdrawal

The pharmaceutical giant AstraZeneca said on Tuesday it is withdrawing its COVID-19 vaccine worldwide due to low demand and following reports that the vaccine caused rare side effects.

AstraZeneca to withdraw its COVID-19 vaccine globally as demand dips, rare side effects revealed

Casey's General Stores

China Fund

Murphy USA

O'Reilly Automotive

Union Pacific

With investors being fearful, it makes sense to look for stocks to buy before the next “Great Reset.” The Great Reset in 2020 was a project with the stated aim to facilitate rebuilding from the global COVID crisis in a way that prioritizes sustainable development.

7 Stocks to Buy Before the Next ‘Great Reset' Begins in 2024

AstraZeneca PLC (LSE:AZN), the FTSE 100's largest constituent, surged 1.8% today after it said it would be withdrawing its COVID vaccine from global markets.  AZ said the decision was because there is a "surplus of available updated vaccines", having admitted months ago that its version can cause a rare and dangerous side effect.

AstraZeneca jumps on covid vaccine withdrawal

Anglo-Swedish drugmaker AstraZeneca is withdrawing its Covid vaccine worldwide, The Telegraph reported on Tuesday.

AstraZeneca to withdraw Covid vaccine worldwide, The Telegraph reports

Eli Lilly

Novo Nordisk

Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

HONG KONG--(BUSINESS WIRE)--Inocras Hong Kong, in partnership with Cancerinformation.com.hk Charity Foundation (CICF) and generously sponsored by AstraZeneca Hong Kong, is pleased to announce the launch of 'HRDetect' Program offering free BRCA or HRD genetic testing for eligible cancer patients in Hong Kong and Macau. The testing services will be performed by the Inocras laboratory in San Diego, which holds CLIA-certified, CAP-accredited to provide the highest quality and reliability of test re.

Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk Charity Foundation and Sponsored by AstraZeneca Hong Kong, Offers Free BRCA or HRD Genetic Testing for Eligible Cancer Patients in Hong Kong and Macau

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes?

Why Astrazeneca (AZN) is a Top Dividend Stock for Your Portfolio

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a leader in liquid biopsy technology, has signed a supplier agreement with AstraZeneca PLC (LSE:AZN) to develop an androgen receptor (AR) detection assay to enhance prostate cancer studies. An extension of a prior arrangement to develop a methodology for detecting CTC micronuclei, the latest collaboration will use ANGLE's innovative Parsortix system.

ANGLE teams up with AstraZeneca on a second assay

ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies GUILDFORD, SURREY / ACCESSWIRE / May 3, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce that it has signed a supplier agreement to develop a Parsortix-based Androgen Receptor1 (AR) detection assay for use in prostate cancer studies. The supplier agreement reported here is with AstraZeneca (LSE/STO/Nasdaq: AZN).

Angle PLC Announces New Commercial Agreement with Large Pharma

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca's CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL). A trend was observed in favor of CALQUEN.

CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial

Kurv Yield Premium Strategy Tesla TSLA ETF

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA).

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

GlaxoSmithKline

Teva Pharmaceutical

The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo Nordisk's diabetes drug Ozempic by making it harder to produce generic drugs.

FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How

AbbVie

WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.

FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'

A dad who suffered a brain injury just days after receiving a British-developed COVID vaccine has told Sky News he would never have had the jab if he had known of the risk of rare but serious side effects.

'A shadow of what I was': Dad who suffered brain injury days after getting COVID jab sues AstraZeneca

AstraZeneca PLC (LSE:AZN) has admitted in court that its Covid-19 vaccines can cause rare side effects. A legal document submitted to London's High Court in February said the vaccine, developed alongside Oxford University, “can, in very rare cases, cause TTS”.

AstraZeneca tells court Covid vaccine can cause rare side effect

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy. A statistically s.

ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06.

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial

News for AstraZeneca Stock (AZN)